PRTC vs. COGT, ARCT, SIGA, AUPH, IRON, YMAB, SVRA, WVE, DNTH, and MLYS
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Cogent Biosciences (COGT), Arcturus Therapeutics (ARCT), SIGA Technologies (SIGA), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Y-mAbs Therapeutics (YMAB), Savara (SVRA), Wave Life Sciences (WVE), Dianthus Therapeutics (DNTH), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical preparations" industry.
PureTech Health (NASDAQ:PRTC) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Cogent Biosciences has a consensus target price of $14.67, indicating a potential upside of 97.13%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than PureTech Health.
0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 5.9% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
PureTech Health's return on equity of 0.00% beat Cogent Biosciences' return on equity.
In the previous week, Cogent Biosciences had 15 more articles in the media than PureTech Health. MarketBeat recorded 15 mentions for Cogent Biosciences and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.87 beat Cogent Biosciences' score of -0.03 indicating that PureTech Health is being referred to more favorably in the media.
Cogent Biosciences received 267 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 70.80% of users gave Cogent Biosciences an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
PureTech Health has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
PureTech Health has higher revenue and earnings than Cogent Biosciences.
Summary
Cogent Biosciences beats PureTech Health on 7 of the 13 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
